Stockreport

Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor [Seeking Alpha]

Zenas BioPharma, Inc.  (ZBIO) 
PDF The company's pipeline is advancing with Orelabrutinib, a potential best-in-class BTK inhibitor, and multiple phase 3 MS trials underway or planned. Obexelimab offers [Read more]